From animal models to gut-on-chip: the challenging journey to capture inter-individual variability in chronic digestive disorders

Aicha Kriaa,Vincent Mariaule,Charlotte De Rudder,Amin Jablaoui,Harry Sokol,Paul Wilmes,Emmanuelle Maguin,Moez Rhimi

DOI: https://doi.org/10.1080/19490976.2024.2333434

IF: 12.2

2024-03-29

Gut Microbes

Abstract:Chronic digestive disorders are of increasing incidence worldwide with expensive treatments and no available cure. Available therapeutic schemes mainly rely on symptom relief, with large degrees of variability in patients' response to such treatments, underlining the need for new therapeutic strategies. There are strong indications that the gut microbiota's contribution seems to be a key modulator of disease activity and patients' treatment responses. Hence, efforts have been devoted to understanding host–microbe interactions and the mechanisms underpinning such variability. Animal models, being the gold standard, provide valuable mechanistic insights into host–microbe interactions. However, they are not exempt from limitations prompting the development of alternative methods. Emerging microfluidic technologies and gut-on-chip models were shown to mirror the main features of gut physiology and disease state, reflect microbiota modification, and include functional readouts for studying host responses. In this commentary, we discuss the relevance of animal models in understanding host–microbe interactions and how gut-on-chip technology holds promises for addressing patient variability in responses to chronic digestive disease treatment.

gastroenterology & hepatology,microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the high individual variability in patients' response to treatment in the treatment of chronic digestive system diseases (such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)). Although current treatment methods mainly focus on relieving symptoms, there are significant differences in the effectiveness of these methods among different patients, indicating the need for new treatment strategies. The study points out that the gut microbiome plays a key role in disease activity and patients' response to treatment. Therefore, understanding the host - microbe interaction and the mechanisms behind it is crucial to solving this problem.

The paper explores the development from animal models to organ - on - chip (gut - on - chip) technology, aiming to better capture the inter - individual differences in chronic digestive system diseases. Although animal models provide valuable mechanistic insights, they also have limitations, such as being unable to fully reflect the complexity and individual differences of human patients. Emerging microfluidic technologies and organ - on - chip models can simulate the main features of intestinal physiology and disease states, reflect changes in the microbiome, and provide functional readings to study host responses. These technologies are expected to overcome the limitations of existing models and provide new tools for personalized medicine.